|Bid||56.83 x 0|
|Ask||56.84 x 0|
|Day's Range||56.06 - 57.50|
|52 Week Range||31.81 - 76.68|
|Beta (3Y Monthly)||5.28|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jun 21, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||76.00|
After recreational marijuana sales were legalized last year, Canopy Growth Corp.’s pot sales jumped 360%. When the world’s largest pot company reports a fresher crop of results this week, that number may be less than 40%.
TORONTO , June 19, 2019 /CNW/ - Canopy Rivers Inc. (the "Company") (RIV.V) (CNPOF) will report its financial results for the fourth quarter and fiscal year ended March 31, 2019 before markets open on Tuesday, July 16, 2019 . The Company's audited consolidated financial statements and Management's Discussion and Analysis for the three and twelve months ended March 31, 2019 will be available on the Company's profile on SEDAR at www.sedar.com and in the Investors section of the Company's website at www.canopyrivers.com. Certain preliminary financial information pertaining to the Company may also be found in the financial results released by Canopy Growth Corporation (TSX: WEED, NYSE: CGC), which are currently scheduled to be released on June 20, 2019 .
SMITHS FALLS, ON , June 19, 2019 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (WEED.TO) (CGC) is pleased to announce that, at a special meeting of the Company's shareholders (the "Meeting") held earlier today, the Company's shareholders voted overwhelmingly in favour of the resolution (the "Canopy Shareholder Resolution") approving the issuance of common shares of Canopy Growth and certain amendments to certain outstanding Company warrants in connection with the Company's previously announced proposed acquisition (the "Transaction") of Acreage Holdings, Inc. ("Acreage").
Cannabis stocks were mostly higher Wednesday, as investors awaited the results of shareholder votes on Canopy Growth Corp.’s proposal to acquire Acreage Holdings Inc. with the companies hosting separate meetings that kick off at 10 a.m.
investors both approved the agreement that the former would acquire its U.S. counterpart for a total of $3.4 billion should cannabis achieve legality at the federal level . Shares of Canopy Growth were rising 0.7% to $42.35 ahead on Wednesday. Canopy isn't actually purchasing Acreage just yet, it's simply buying the rights to purchase the company as soon as cannabis is legalized on the federal level in the U.S.
The energy drink space may have a lesson for the budding cannabis industry, Bank of America Merrill Lynch says. While there was all kinds of buzz around energy drinks when Red Bull came along in 1997, ...
On June 19, Canopy Growth (WEED) (CGC) and CURE Pharmaceutical announced a partnership to create a new CBD-based oral delivery thin film. The oral thins will be available for distribution globally.
The companies will be working on a low-dose CBD oral thin film that will use CURE Pharmaceutical's patented CUREfilm technology. Canopy Growth will license the technology for global distribution. CUREfilm will offer Canopy Growth a dosage that is "ideal for administering cannabinoids," CURE said in a statement.
CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it is collaborating with Canopy Growth Corporation (WEED.TO) (CGC), (“Canopy”) to develop a new low-dose cannabidiol (CBD) oral thin film (OTF) using CURE’s patented CUREfilm™ technology for global distribution. “This collaboration builds on our licensing agreement with Canopy and accelerates product commercialization,” said Rob Davidson, CEO of CURE Pharmaceutical. CURE is registered with the U.S. Drug Enforcement Agency (DEA) to develop and manufacture cannabis-derived and synthetic cannabinoid-based products using its CUREfilm technology at its facility in Oxnard, Calif. With CUREfilm, the delivery of cannabinoids is easier and more effective as it offers increased bioavailability, ease and precision of dosing and greater palatability.
Canadian cannabis company Canopy Growth is scheduled to report fiscal fourth-quarter 2019 earnings on Thursday after the market closes.
Canopy Growth is making progress in the Australian market through its Spectrum Therapeutics brand, which caters to the demand for medical cannabis products. According to the company, the number of medical patients in the country has increased ten times in the last year.
New York has been on the fence about legalizing marijuana. In a series of tweets, New York City Mayor Bill De Blasio expressed strong support for legalizing cannabis the “RIGHT way.”
On June 18, Canopy Growth (WEED) (CGC) announced another international development: it has entered into an agreement with Procaps in Colombia. According to Canopy Growth, Procaps is active across the world, exporting its products to over 50 international markets.
On June 20, Canopy Growth (WEED) (CGC) is expected to report sales of 91.1 million Canadian dollars and a gross income of 24.4 million Canadian dollars. The company's margins are expected to compress.
On June 20, Canopy Growth (WEED) (CGC) is scheduled to announce its fourth-quarter and fiscal 2019 earnings after the market closes. The company's guidance will likely set the tone for the cannabis industry's near-term expectations.
Cannabis stocks are mixed, with market leader Canopy Growth Corp. gaining after it announced its latest growth moves ahead of Wednesday’s shareholder vote on its proposal to acquire Acreage Holdings.
Canopy said it will leverage Procaps’ encapsulation capacity. The Canopy subsidiary Spectrum Therapeutics has completed sales to patients in Chile and Brazil, the company said. In Australia, Spectrum received its first medical cannabis oil shipment in April, with sales commencing the following month.
The tech-heavy Nasdaq led the way early Monday. Top growth stock Lululemon is regaining a buy point in today's stock market action.
SMITHS FALLS, Ontario, June 17, 2019 /PRNewswire/ -- Canopy Growth Corporation ("Canopy Growth" or the "Company") (WEED.TO)(CGC) is pleased to highlight recent developments that are fueling its international progress in emerging medical cannabis and CBD markets. The Company's global three-prong strategy includes a focus on building best-in-class global GMP (Good Manufacturing Practices) infrastructure, advancing clinical research programs and best-in-class education and sales programs through its Spectrum Therapeutics medical division, and launching CBD products where regulatory environments allow.
Last week was quite eventful for the cannabis industry, with Colorado reaching $1.0 billion in sales and Kroger Co (NYSE: KR ) announcing plans to start carrying CBD products. Here’s what you should keep ...
SMITHS FALLS, ON , June 17, 2019 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (WEED.TO)(CGC) is pleased to highlight recent developments that are fueling its international progress in emerging medical cannabis and CBD markets. The Company's global three-prong strategy includes a focus on building best-in-class global GMP (Good Manufacturing Practices) infrastructure, advancing clinical research programs and best-in-class education and sales programs through its Spectrum Therapeutics medical division, and launching CBD products where regulatory environments allow.